Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (O ...
Scientists have unveiled a breakthrough imaging method that can capture the hidden details of events unfolding in trillionths ...
Have you ever wished to drive microscopic matter along an arbitrarily tailored trajectory instead of just a circle? That's ...
A novel imaging method captures ultrafast events with unprecedented detail by combining laser encoding and AI reconstruction. Researchers have introduced a new imaging method that reveals far more ...
Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at ...
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints metClinically meaningful microbiome ...
Researchers have developed a new imaging technique that captures more information about ultrafast processes in the ...
MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, developed a technology based on quantum key distribution protocol and quantum random number ...
Researchers have developed a new imaging technique that captures more information about ultrafast processes in the microscopic world than was previously possible.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results